Improvements in the Long-Term Outcome of Crohn's Disease over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort

American Journal of Gastroenterology

Volumn 112, Issue 2, 2017, Pages 325-336

  Jeuring, Steven F G ^a   Van Den Heuvel, Tim R A ^a   Liu, Limmie Y L ^a   Zeegers, Maurice P ^a   Hameeteman, Wim H ^a   Romberg Camps, Mariëlle J L ^b   Oostenbrug, Liekele E ^b   Masclee, Ad A M ^a   Jonkers, Daisy M A E ^a   Pierik, Marieke J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DISEASE COURSE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; ABDOMINAL SURGERY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; TRENDS; YOUNG ADULT;

6-MERCAPTOPURINE; ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; BIOLOGICAL PRODUCTS; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; PREDNISONE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85001781144     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.524     Document Type: Article

References (49)

1. Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
2. Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-30.
3. Silverstein MD, Lofus EV, Sandborn WJ et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57.
4. Faubion WA Jr, Lofus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
5. Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis 2012; 30(Suppl 3): 67-72.
6. van Bodegraven AA, van Everdingen JJ, Dijkstra G et al. [Guideline 'Diagnosis and treatment of inflammatory bowel disease in adults'. I. Diagnosis and treatment]. Ned Tijdschr Geneeskd 2010; 154: A1899.
7. Dignass A, Van Assche G, Lindsay JO et al. The second European evidencebased Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
8. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting Terapeutic Targets in inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110: 1324-38.
9. Szklo M. Population-based cohort studies. Epidemiol Rev 1998; 20: 81-90.
10. Gower-Rousseau C, Savoye G, Colombel JF et al. Are we improving disease outcomes in IBD? A view from the epidemiology side. Gut 2014; 63: 1529-30.
11. Peyrin-Biroulet L, Lofus EV Jr, Colombel JF et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
12. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
13. Tarrant KM, Barclay ML, Frampton CM et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-93.
14. Lovasz BD, Lakatos L, Horvath A et al. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort. World J Gastroenterol 2013; 19: 2217-26.
15. Lakatos PL, Golovics PA, David G et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012; 107: 579-88.
16. Nguyen GC, Nugent Z, Shaw S et al. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141: 90-7.
17. Rungoe C, Langholz E, Andersson M et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014; 63: 1607-16.
18. Ramadas AV, Gunesh S, Tomas GA et al. Natural history of Crohn's disease in a population-based cohort from Cardi? (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
19. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
20. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
21. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
22. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
23. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004; (1): CD003574.
24. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (1): CD006893.
25. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2013; (4): CD000545.
26. Chande N, Patton PH, Tsoulis DJ et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2015; (10): CD000067.
27. Centraal Bureau voor de Statistiek. CBS StatLine-Bevolkingsontwikkeling; levendgeborenen, overledenen en migratie per regio 2015.
28. van den Heuvel TR, Jonkers DM, Jeuring SF et al. Cohort profile: the inflammatory Bowel Disease South Limburg Cohort (IBDSL). Int J Epidemiol 2015; pii: dyv088.
29. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classifcation of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
30. Gasche C, Scholmerich J, Brynskov J et al. A simple classifcation of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
31. Targownik LE, Nugent Z, Singh H et al. Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 622-30.
32. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text, 3rd edn Springer-Verlag: New York, 2012.
33. Walker AM. Confounding by indication. Epidemiology 1996; 7: 335-6.
34. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9.
35. Vester-Andersen MK, Vind I, Prosberg MV et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011-a Danish population-based cohort study. J Crohns Colitis 2014; 8: 1675-83.
36. Vester-Andersen MK, Prosberg MV, Jess T et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year followup study in the era of immunomodulating therapy. Am J Gastroenterol 2014; 109: 705-14.
37. Vegh Z, Burisch J, Pedersen N et al. Treatment steps, surgery, and hospitalization rates during the first year of follow-up in patients with inflammatory bowel diseases from the 2011 ECCO-Epicom Inception Cohort. J Crohns Colitis 2015; 9: 747-53.
38. van der Valk ME, Mangen MJ, Leenders M et al. Healthcare costs of inflammatory bowel disease have shifed from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014; 63: 72-9.
39. Rieder F, Zimmermann EM, Remzi FH et al. Crohn's disease complicated by strictures: a systematic review. Gut 2013; 62: 1072-84.
40. Scharl M, Rogler G. Pathophysiology of fstula formation in Crohn's disease. World J Gastrointest Pathophysiol 2014; 5: 205-12.
41. Allen PB, Peyrin-Biroulet L. Moving towards disease modifcation in inflammatory bowel disease therapy. Curr Opin Gastroenterol 2013; 29: 397-404.
42. Picco MF, Zubiaurre I, Adluni M et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol 2009; 104: 2754-9.
43. Peyrin-Biroulet L, Oussalah A, Williet N et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-6.
44. Kariyawasam VC, Selinger CP, Katelaris PH et al. Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease. Inflamm Bowel Dis 2014; 20: 1382-90.
45. Safroneeva E, Vavricka SR, Fournier N et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther 2015; 42: 977-89.
46. Wise L. Risks and benefts of (pharmaco)epidemiology. Ther Adv Drug Saf 2011; 2: 95-102.
47. Torres J, Caprioli F, Katsanos KH et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis 2016; 10: 1385-94.
48. Suissa S. Immortal time bias in observational studies of drug Effects. Pharmacoepidemiol Drug Saf 2007; 16: 241-9.
49. Targownik LE, Suissa S. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research. Am J Gastroenterol 2015; 110: 1647-50.